HIKMA PHARMACEUTICALS

The pharmaceutical CDMO market is projected to grow from USD 173.2 billion in 2023 to USD 345.6 billion by 2033, driven by the rise in disorder prevalence. Asia Pacific led with a 43% share in 2023, while North America is expected to grow fastest. The API segment dominated in 2023, and the drug segment is forecasted to grow rapidly. Solid dosage forms and pain indications were the largest segments in 2023. Big pharmaceutical companies led the market, with increasing collaborations between CDMOs and pharmaceutical firms. Technological advancements, such as AI and IoT, present opportunities for market growth.

The DEA approved Takeda Pharmaceuticals to increase Vyvanse production by 24% to address ongoing ADHD drug shortages, with a 13,478-pound increase including 3434 pounds for domestic and 10,313 pounds for foreign demand.

The U.S. DEA approved Takeda Pharmaceuticals to increase Vyvanse production by 24% due to ongoing ADHD drug shortages, with 13,478 pounds allocated for domestic and foreign demand.